As of 2024-12-14, the Relative Valuation of Y-mAbs Therapeutics, Inc (YMAB) is (11.93) USD. This relative valuation is based on P/E multiples. With the latest stock price at 9.43 USD, the upside of Y-mAbs Therapeutics, Inc based on Relative Valuation is -226.6%.
The range of the Relative Valuation is (11.04) - (10.24) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.7x - 31.0x | 25.8x |
| Forward P/E multiples | 18.7x - 19.2x | 19.0x |
| Fair Price | (11.04) - (10.24) | (11.93) |
| Upside | -217.1% - -208.6% | -226.6% |
| Date | P/E |
| 2024-12-12 | -18.34 |
| 2024-12-11 | -18.79 |
| 2024-12-10 | -19.29 |
| 2024-12-09 | -19.26 |
| 2024-12-06 | -19.78 |
| 2024-12-05 | -19.33 |
| 2024-12-04 | -19.48 |
| 2024-12-03 | -19.84 |
| 2024-12-02 | -22.13 |
| 2024-11-29 | -22.37 |
| 2024-11-27 | -22.30 |
| 2024-11-26 | -20.21 |
| 2024-11-25 | -19.82 |
| 2024-11-22 | -19.54 |
| 2024-11-21 | -18.96 |
| 2024-11-20 | -19.78 |
| 2024-11-19 | -20.38 |
| 2024-11-18 | -20.12 |
| 2024-11-15 | -20.91 |
| 2024-11-14 | -21.75 |
| 2024-11-13 | -24.74 |
| 2024-11-12 | -24.74 |
| 2024-11-11 | -27.91 |
| 2024-11-08 | -29.05 |
| 2024-11-07 | -29.19 |
| 2024-11-06 | -29.45 |
| 2024-11-05 | -28.34 |
| 2024-11-04 | -27.91 |
| 2024-11-01 | -27.67 |
| 2024-10-31 | -27.23 |
| 2024-10-30 | -27.87 |
| 2024-10-29 | -27.67 |
| 2024-10-28 | -27.80 |
| 2024-10-25 | -27.18 |
| 2024-10-24 | -27.48 |
| 2024-10-23 | -27.91 |
| 2024-10-22 | -27.87 |
| 2024-10-21 | -27.33 |
| 2024-10-18 | -27.12 |
| 2024-10-17 | -26.65 |
| 2024-10-16 | -27.61 |
| 2024-10-15 | -26.84 |
| 2024-10-14 | -27.29 |
| 2024-10-11 | -27.21 |
| 2024-10-10 | -25.92 |
| 2024-10-09 | -26.39 |
| 2024-10-08 | -26.54 |
| 2024-10-07 | -26.35 |
| 2024-10-04 | -26.58 |
| 2024-10-03 | -25.38 |